Datapoint: Viatris Sells Biosimilar Business to Biocon

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
March 2

Viatris, the manufacturer of the first interchangeable biosimilar, on Monday revealed it will sell its biosimilar business to partner Biocon Biologics in a $3.3 billion deal. This includes Semglee, the insulin interchangeable with Sanofi’s Lantus. The drug launched in November 2021. For the treatment of type 2 diabetes, Semglee currently holds covered or better status for 59% of all insured lives, to Lantus’ 70%.

SOURCE: MMIT Analytics, as of 3/1/22

0
0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: North Carolina Medicaid Expansion Set for Dec. 1

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: New Mexico Orders Payers to Expand Behavioral Health Access

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 26

Datapoint: CMS Reinstates Medicaid Coverage for 500,000 People

Read More

The Latest

enhance-patient-assistance-programs

Meet Our Reporters

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today